1. Home
  2. RDHL vs HCWB Comparison

RDHL vs HCWB Comparison

Compare RDHL & HCWB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

RDHL

Redhill Biopharma Ltd.

HOLD

Current Price

$0.53

Market Cap

3.3M

Sector

Health Care

ML Signal

HOLD

Logo HCW Biologics Inc.

HCWB

HCW Biologics Inc.

BUY

Current Price

$1.48

Market Cap

3.6M

Sector

Health Care

ML Signal

BUY

Company Overview

Basic Information
Metric
RDHL
HCWB
Founded
2009
2018
Country
Israel
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
3.3M
3.6M
IPO Year
2012
2021

Fundamental Metrics

Financial Performance
Metric
RDHL
HCWB
Price
$0.53
$1.48
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
★ 869.5K
748.9K
Earning Date
09-30-2026
11-13-2026
Dividend Yield
N/A
N/A
EPS Growth
★ N/A
N/A
EPS
★ N/A
N/A
Revenue
N/A
★ $4,099,750.00
Revenue This Year
$17,592.31
$12,215.61
Revenue Next Year
$25.89
N/A
P/E Ratio
N/A
★ N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.44
$0.86
52 Week High
$2.14
$27.30

Technical Indicators

Market Signals
Indicator
RDHL
HCWB
Relative Strength Index (RSI) 45.63 31.82
Support Level N/A $0.86
Resistance Level $1.07 $3.07
Average True Range (ATR) 0.05 0.22
MACD 0.01 0.02
Stochastic Oscillator 34.96 1.21

Price Performance

Historical Comparison
RDHL
HCWB

About RDHL Redhill Biopharma Ltd.

RedHill Biopharma Ltd is a specialty biopharmaceutical company mainly focused on the U.S. development and commercialization of drugs for GI diseases, infectious diseases, and oncology. The Company is mainly focused on the advancement of its development pipeline of clinical-stage therapeutic candidates and also commercializes its GI-related product, Talicia (omeprazole, amoxicillin, and rifabutin) in the U.S. Its therapeutic candidates include opaganib, RHB-204, RHB-104, RHB-102 (Bekinda), and RHB-107.

About HCWB HCW Biologics Inc.

HCW Biologics Inc is a clinical-stage biopharmaceutical company developing transformative fusion immunotherapeutics to support or treat diseases promoted by chronic inflammation. It has created novel compounds that represent a new class of drugs that it believes has the potential to fundamentally change the treatment of autoimmune disorders and other proinflammatory diseases, cancer and senescence-associated dysplasia. The company has developed two proprietary drug discovery and development platforms which it uses to create novel fusion immunotherapeutics: The TOBI (Tissue factOr-Based fusIon) platform, and The T-cell Receptor Beta Chain constant region (TRBC) platform. It operates and manages its business as one reportable segment.

Share on Social Networks: